Predictive value of thymidylate synthase expression in gastric cancer: A systematic review with meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 261-267

  Hu, Hua Bin ^a   Kuang, Lei ^b   Zeng, Xiao Min ^c   Li, Bin ^a   Liu, En Yi ^a   Zhong, Mei Zuo ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Fluoropyrimidine; Gastric cancer; Meta analysis; Thymidylate synthase

Indexed keywords

THYMIDYLATE SYNTHASE;

CLINICAL TRIAL (TOPIC); ENZYMOLOGY; HUMAN; META ANALYSIS (TOPIC); METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; REVIEW; STOMACH TUMOR; SURVIVAL RATE;

CLINICAL TRIALS AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; THYMIDYLATE SYNTHASE;

EID: 84864882258     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.261     Document Type: Article

References (48)

1. Akamoto S, Usuki H, Haba R, et al (2008). The discrepancy in thymidylate synthase and dihydropyrimidine dehydrogenase expression depending on measurement methodologies in stage 4 gastric cancer. Hepatogastroenterology, 55, 1882-6.
2. Altman DG, Lausen B, Sauerbrei W, et al (1994). Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst, 86, 829-35.
3. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
4. Berger SH, Jenh CH, Johnson LF, et al (1985). Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol, 28, 461-7.
5. Boku N, Chin K, Hosokawa K, et al (1998). Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cisplatinum. Clin Cancer Res, 4, 1469-74.
6. Boku N, Ohtsu A, Yoshida S, et al (2007). Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol, 37, 275-81.
7. Cho MY, Yi SY, Eom M, et al (2006). A high thymidylate synthase expression is related to better outcome for advanced gastric cancer patients treated with 5-FU chemotherapy after curative resection. Korean J Pathol, 40, 128-36.
8. Choi IS, Lee HS, Lee KW, et al (2011). Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med Oncol, 28, 991-8.
9. Choi J, Lim H, Nam DK, et al (2001). Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer, 84, 186-92.
10. Chung-Kang C, Ohno M, Nishimura K, et al (2006). Intratumoral heterogeneous expression of thymidylate synthase in gastric cancer. Hepatogastroenterology, 53, 458-62.
11. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
12. Fukuda H, Takiguchi N, Koda K, et al (2006). Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest, 24, 235-41.
13. Hayden JA, Cote P, Bombardier C (2006). Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med, 144, 427-37.
14. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
15. Hua D, Huang ZH, Mao Y, et al (2007). Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol, 13, 5030-4.
16. Ichikawa W, Takahashi T, Suto K, et al (2004). Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer, 91, 1245-50.
17. Ichikawa W, Takahashi T, Suto K, et al (2006). Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer, 119, 1927-33.
18. Ishido K, Azuma M, Koizumi W, et al (2009). Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy. Pharmacogenet Genomics, 2009, Nov 5.
19. Ishikawa Y, Kubota T, Otani Y, et al (1999). Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res, 19, 5635-40.
20. Ishizone S, Maruta F, Saito H, et al (2006). Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy, 52, 301-7.
21. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
22. Jeung HC, Rha SY, Shin SJ, et al (2011). Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anticancer Drugs, 22, 801-10.
23. Jeong SH, Han JH, Kim JH, et al (2011). Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci, 56, 131-8.
24. Johnston PG, Drake JC, Trepel J, et al (1992). Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res, 52, 4306-12.
25. Kim KH, Kwon HC, Oh SY, et al (2011). Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers, 16, 74-82.
26. Kim JS, Kim MA, Kim TM, et al (2009). Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer, 100, 732-8.
27. Koizumi W, Narahara H, Hara T, et al (2008). S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol, 9, 215-21.
28. Koizumi W, Tanabe S, Azuma M, et al (2010). Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer, 126, 162-70.
29. Kuniyasu T, Nakamura T, Tabuchi Y, et al (1998). Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. CANCER, 83, 1300-6.
30. Kwon HC, Roh MS, Oh SY, et al (2007). Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 18, 504-9.
31. Lenz HJ, Leichman CG, Danenberg KD, et al (1996). Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol, 14, 176-82.
32. Lee J, Park CK, Park JO, et al (2008). Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res, 14, 82-8.
33. Liu JM, Chen LT, Li AF, et al (2004). Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. Jpn J Clin Oncol, 34, 727-32.
34. Matsubara J, Nishina T, Yamada Y, et al (2008). Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer, 98, 832-9.
35. Metzger R, Leichman CG, Danenberg KD, et al (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol, 16, 309-16.
36. Miyamoto S, Boku N, Ohtsu A, et al (2000). Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol, 17, 653-8.
37. Napieralski R, Ott K, Kremer M, et al (2005). Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res, 11, 3025-31.
38. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
39. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N ENGL J MED, 357, 1810-20.
40. Santi DV, McHenry CS, Sommer H (1974). Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry, 13, 471-81.
41. Suda Y, Kuwashima Y, Tanaka Y, et al (1999). Expression of thymidylate synthase and thymidine phosphorylase in recurrence and survival rates of advanced gastric cancer. Gastric Cancer, 2, 165-72.
42. Tahara M, Ochiai A, Fujimoto J, et al (2004). Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep, 11, 9-15.
43. Terashima M, Fujiwara H, Takagane A, et al (2003). Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer, 1, 71-81.
44. Tsujitani S, Konishi I, Suzuki K, et al (2000). Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients. J Exp Clin Cancer Res, 19, 189-95.
45. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7
46. Wei J, Zou Z, Qian X, et al (2008) ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer, 98, 1398-402.
47. Yeh CN, Jung SM, Chen TW, et al (2010). Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracilbased adjuvant chemotherapy. Langenbecks Arch Surg, 395, 217-25.
48. Yeh KH, Shun CT, Chen CL, et al (1998). High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer, 82, 1626-31.